January 2025 | Blood Cancers Today

January 2025

This issue of Blood Cancers Today includes a feature on quadruplet therapy in MM; a Get to Know with Craig Cole, MD; meeting news from ASH 2024; and more.

Features

Get to Know

Get to Know ... Craig Cole, MD

In Focus

More Is More: Quadruplets Gain a Foothold as Standard in Newly Diagnosed MM

News

Regulatory Actions

FDA Approves First Menin Inhibitor for Relapsed, Refractory Acute Leukemia With KMT2A Translocation

Obe-cel Receives FDA Approval for Relapsed, Refractory B-ALL

Remestemcel-L Now an FDA Approved Treatment for Pediatric SR-aGVHD

FDA Grants Fast Track Designation to LYT-200 for AML

FDA Speeds Up Development of Relmacabtagene Autoleucel for Relapsed or Refractory LBCL

FDA Approves Acalabrutinib With Bendamustine and Rituximab for Frontline MCL

Meeting News

Venetoclax Plus Obinutuzumab Superior to FCR-BR for Patients With CLL

Liso-cel Versus Mosunetuzumab in Follicular Lymphoma: Cost, Clinical Outcomes, Time Toxicity

Early Study Looks at Combining HMA with Immunotherapy-Based Regimens in MDS

First-in-Human Phase I Study Results Presented: Trispecific CAR T-Cell Therapy

Reaching for the Holy Grail in Myelofibrosis With Imetelstat Combinations

News Roundup

NCCN Awards Grants to Three Research Projects for CLL, SLL

FDA, HHS Work on Recommendations Regarding Inclusion of Tissue Biopsies in Clinical Trials

Editor's Picks

All-Oral SAVE Regimen Achieves High Rates of Remission in Relapsed or Refractory AML

Enhanced AML Remission With Cladribine Alternating Therapy

HemOnc Happenings

ASH Announces Honorific Awards at 66th Annual Meeting

January 2025

Advertisement

Advertisement